Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study
Authors' conclusion
In a randomized, blinded, phase III LTE study, maintenance of disease control following induction of sustained LDA/REM with baricitinib 4 mg was greater with continued 4 mg than after tapering to 2 mg.
Study context
- Population
- Patients with rheumatoid arthritis (RA) in a baricitinib phase III long-term extension (LTE) who received baricitinib 4 mg for ≥ 15 months and maintained Clinical Disease Activity Index (CDAI) low disease activity (LDA) or remission (REM)
- Comparison
- Continued baricitinib 4 mg vs tapering to 2 mg
- Primary endpoint
- Maintenance of CDAI LDA (NRI)
- Follow-up
- Up to 96 weeks
Methodological detailsblinded, phase III, long-term extension, dose step-down, nonresponder imputation
- Blinded
- Phase III
- Long-term extension
- Dose step-down
- Nonresponder imputation
Primary result
As reported in the abstract
Maintained CDAI LDA (NRI)
Further findings
Maintained CDAI REM · up to 96 weeks
Rescue rates
Regained LDA after rescue from 2 mg to 4 mg (n=112 who lost LDA) · 12 and 24 weeks postrescue
- Achieved LDA again at 12 weeks postrescue
- 76.2%
- Achieved LDA again at 24 weeks postrescue
- 75.6%
Original publication
Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study. J Rheumatol. Published 15 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →